May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 20, 2026

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Conexiant

May 20, 2026

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Conexiant

May 19, 2026

Top 10 High-Impact Clinical Guidance Updates for Board-Certified Physicians

A structured framework of guidelines, consensus statements, therapies, and clinical tools used across practice.

Conexiant

May 19, 2026

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

Conexiant

May 19, 2026

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Cross-sectional study linked higher cardiovascular health scores with fewer respiratory symptoms and higher lung function measures among US adults

Conexiant

May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Conexiant

May 18, 2026

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.

Conexiant

May 14, 2026

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Conexiant

May 14, 2026

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Conexiant